Non-invasive prenatal testing (NIPT) analyzes cell-free DNA circulating in maternal blood to screen for certain chromosomal conditions in a developing fetus. Expected values for these tests typically fall within established parameters, indicating a low probability of these specific aneuploidies. For example, a result might show a low risk for trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). These assessments are usually presented as probabilities or risk scores, rather than definitive diagnoses.
Accurate interpretation of these values is crucial for providing expectant parents with reliable information about their pregnancy. This allows for informed decision-making regarding further diagnostic testing, such as chorionic villus sampling (CVS) or amniocentesis, if warranted. The development and refinement of NIPT has significantly advanced prenatal screening, offering a safer and less invasive option compared to traditional methods. This advancement has expanded access to valuable information about fetal health, empowering expectant parents and healthcare providers alike.